Real-world study of ixekizumab (Taltz) in the treatment of psoriasis

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000034601

Enrollment

Unknown

Registered

2020-07-11

Start date

2020-07-15

Completion date

Unknown

Last updated

2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriasis

Interventions

case series:Treatment of Taltz

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. All psoriasis patients using Taltz; 2. Patients are willing to paticipents this trial and sign the infomed consent.

Exclusion criteria

Exclusion criteria: Other situations not suitable for inclusion.

Design outcomes

Primary

Measure	Time frame
psoriasis area and severity index;	—

Countries

China

Contacts

Public ContactYuling Shi

Shanghai Skin Disease Hospital

shiyuling1973@tongji.edu.cn+86 13816213884

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026